XOMA to receive $8.1M from Viracta after Day One sells PRV for $108M

XOMA Royalty Corp

Day One Biopharmaceuticals sold a priority review voucher for $108M after FDA approval of OJEMDA.
XOMA is entitled to $8.1M from Viracta under a March 2021 agreement covering tovorafenib milestones.
The PRV sale proceeds trigger event-based economics payable to XOMA.
Funds represent a portion of the PRV proceeds passed through from Day One to Viracta.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.